Claudette Falato

475 total citations
20 papers, 261 citations indexed

About

Claudette Falato is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Claudette Falato has authored 20 papers receiving a total of 261 indexed citations (citations by other indexed papers that have themselves been cited), including 15 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 10 papers in Cancer Research. Recurrent topics in Claudette Falato's work include Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (8 papers). Claudette Falato is often cited by papers focused on Advanced Breast Cancer Therapies (10 papers), Breast Cancer Treatment Studies (10 papers) and HER2/EGFR in Cancer Research (8 papers). Claudette Falato collaborates with scholars based in Spain, Sweden and United States. Claudette Falato's co-authors include Jonas Bergh, Theodoros Foukakis, Tomás Pascual, Aleix Prat, Fara Brasó‐Maristany, Francesco Schettini, Linda S. Lindström, Julie Lorent, Paul K. Wright and Carmine De Angelis and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Claudette Falato

20 papers receiving 259 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Claudette Falato Spain	10	161	107	78	78	41	20	261
Laura Arthur United Kingdom	9	153 1.0×	139 1.3×	102 1.3×	74 0.9×	33 0.8×	21	271
Anna Barbro Sætersdal Norway	7	197 1.2×	125 1.2×	96 1.2×	61 0.8×	34 0.8×	7	284
Orsolya Rusz Hungary	10	197 1.2×	101 0.9×	144 1.8×	118 1.5×	53 1.3×	19	317
Michał Marek Hoppe Singapore	5	171 1.1×	70 0.7×	165 2.1×	52 0.7×	35 0.9×	9	263
Pablo Tolosa Spain	8	154 1.0×	50 0.5×	61 0.8×	91 1.2×	19 0.5×	36	229
Beige Zong China	10	125 0.8×	119 1.1×	167 2.1×	66 0.8×	21 0.5×	15	321
Giulia Cursano Italy	9	102 0.6×	87 0.8×	65 0.8×	49 0.6×	16 0.4×	14	192
German Demidov Germany	8	91 0.6×	42 0.4×	77 1.0×	39 0.5×	43 1.0×	15	204
Mitsugu Yamamoto Japan	7	252 1.6×	147 1.4×	68 0.9×	88 1.1×	32 0.8×	12	336
Anca Mera United Kingdom	9	183 1.1×	170 1.6×	122 1.6×	49 0.6×	38 0.9×	16	325

Countries citing papers authored by Claudette Falato

Since Specialization

Citations

This map shows the geographic impact of Claudette Falato's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Claudette Falato with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Claudette Falato more than expected).

Fields of papers citing papers by Claudette Falato

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Claudette Falato. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Claudette Falato. The network helps show where Claudette Falato may publish in the future.

Co-authorship network of co-authors of Claudette Falato

This figure shows the co-authorship network connecting the top 25 collaborators of Claudette Falato. A scholar is included among the top collaborators of Claudette Falato based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Claudette Falato. Claudette Falato is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Razavi, Pedram, et al.. (2025). Prediction of real-world progression free survival (rwPFS) using a multimodal machine learning (ML) model for patients with HR+ HER2- metastatic breast cancer (mBC) undergoing first line (1L) treatment with cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) and endocrine therapy (ET).. Journal of Clinical Oncology. 43(16_suppl). 1 indexed citations

Schettini, Francesco, Olga Martínez‐Sáez, Claudette Falato, et al.. (2023). Prognostic value of intrinsic subtypes in hormone-receptor-positive metastatic breast cancer: systematic review and meta-analysis. ESMO Open. 8(3). 101214–101214. 8 indexed citations

Schettini, Francesco, Fara Brasó‐Maristany, Tomás Pascual, et al.. (2023). 275P Clinical and molecular impact of neoadjuvant chemotherapy (NACT) or endocrine therapy (NET) on hormone receptor positive (HR+)/HER2-negative (-) breast cancer (BC). Annals of Oncology. 34. S294–S294. 1 indexed citations

Oliveira, Mafalda, Tomás Pascual, Mireia Margelí Vila, et al.. (2023). 124O Patritumab deruxtecan (HER3-DXd) in hormonal receptor-positive/HER2-negative (HR+/HER2-) and triple-negative breast cancer (TNBC): Results of part B of SOLTI TOT-HER3 window of opportunity trial. ESMO Open. 8(1). 101463–101463. 6 indexed citations

Vidal, María, Tomás Pascual, Claudette Falato, et al.. (2023). Abstract PD13-01: PD13-01 Elacestrant in postmenopausal women with estrogen receptor positive and HER2-negative early breast cancer: primary efficacy and safety analysis of the preoperative, window of opportunity SOLTI-1905-ELIPSE trial. Cancer Research. 83(5_Supplement). PD13–1. 10 indexed citations

Villacampa, Guillermo, Claudette Falato, Laia Paré, et al.. (2022). Pre-operative ribociclib plus letrozole versus chemotherapy: Health-related quality of life outcomes from the SOLTI CORALLEEN trial. European Journal of Cancer. 174. 232–242. 4 indexed citations

Cejalvo, Juan Miguel, Claudette Falato, Lorea Villanueva, et al.. (2022). Oncolytic viruses: A new immunotherapeutic approach for breast cancer treatment?. Cancer Treatment Reviews. 106. 102392–102392. 18 indexed citations

Prat, Aleix, Claudette Falato, Olga Martínez‐Sáez, et al.. (2022). LBA3 Patritumab deruxtecan (HER3-DXd) in early-stage HR+/HER2- breast cancer: Final results of the SOLTI TOT-HER3 window of opportunity trial. Annals of Oncology. 33. S164–S164. 9 indexed citations

Villacampa, Guillermo, Laia Paré, Cristina Hernándo, et al.. (2022). Abstract P4-10-04: Health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative, luminal B breast cancer patients treated with ribociclib plus letrozole or chemotherapy. Cancer Research. 82(4_Supplement). P4–10. 1 indexed citations

10.

Falato, Claudette, Francesco Schettini, Tomás Pascual, Fara Brasó‐Maristany, & Aleix Prat. (2022). Clinical implications of the intrinsic molecular subtypes in hormone receptor-positive and HER2-negative metastatic breast cancer. Cancer Treatment Reviews. 112. 102496–102496. 39 indexed citations

11.

Bellet, Meritxell, Serafín Morales, Kepa Amillano, et al.. (2022). Abstract P1-07-02: Primary results of ONAWA (SOLTI-1802) trial: A window of opportunity trial of onapristone in postmenopausal women with progesterone receptor-positive/HER2-negative early breast cancer (EBC). Cancer Research. 82(4_Supplement). P1–7. 2 indexed citations

12.

Pascual, Tomás, María Vidal, Mafalda Oliveira, et al.. (2022). Abstract P2-14-13: Talimogene laherparepvec (T-VEC) + atezolizumab combination in early breast cancer (SOLTI-1503 PROMETEO): Safety and efficacy interim analysis. Cancer Research. 82(4_Supplement). P2–14. 1 indexed citations

13.

Gamper, Eva‐Maria, Jammbe Musoro, Corneel Coens, et al.. (2021). Minimally important differences for the EORTC QLQ-C30 in prostate cancer clinical trials. BMC Cancer. 21(1). 1083–1083. 17 indexed citations

14.

Stadler, Rudolf, Pablo L. Ortiz‐Romero, M. Bagot, et al.. (2021). Phase II trial of atezolizumab (anti-PD-L1) in the treatment of stage IIb–IVB mycosis fungoides/Sézary syndrome patients relapsed/refractory after a previous systemic treatment (PARCT). European Journal of Cancer. 156. S22–S23. 7 indexed citations

15.

Falato, Claudette, Sara Taylor, Robert Szulkin, et al.. (2018). Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry. Breast Cancer Research and Treatment. 172(3). 703–712. 4 indexed citations

16.

Lundberg, Arian, Linda S. Lindström, J. Chuck Harrell, et al.. (2017). Gene Expression Signatures and Immunohistochemical Subtypes Add Prognostic Value to Each Other in Breast Cancer Cohorts. Clinical Cancer Research. 23(24). 7512–7520. 34 indexed citations

17.

Falato, Claudette, Nicholas P. Tobin, Julie Lorent, et al.. (2015). Intrinsic subtypes and genomic signatures of primary breast cancer and prognosis after systemic relapse. Molecular Oncology. 10(4). 517–525. 16 indexed citations

18.

Falato, Claudette, et al.. (2014). A retrospective safety and efficacy analysis of the first patients treated with eribulin for metastatic breast cancer in Stockholm, Sweden. Acta Oncologica. 54(4). 527–534. 16 indexed citations

19.

Falato, Claudette, Julie Lorent, Edneia Tani, et al.. (2014). Ki67 measured in metastatic tissue and prognosis in patients with advanced breast cancer. Breast Cancer Research and Treatment. 147(2). 407–414. 22 indexed citations

20.

Arpino, Grazia, Carmine De Angelis, Mario Giuliano, et al.. (2009). Molecular Mechanism and Clinical Implications of Endocrine Therapy Resistance in Breast Cancer. Oncology. 77(Suppl. 1). 23–37. 45 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact